Traws Pharma, Inc. (TRAW) has a negative trailing P/E of -0.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -105.63%, forward earnings yield 39.84%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2015 | -0.9 | 0.01 | 2.18 | 1.91 | - |
| 2016 | -0.5 | 0.01 | 2.34 | 1.81 | - |
| 2017 | -0.6 | 0.01 | -1.15 | 17.15 | - |
| 2018 | -0.4 | 0.00 | 1.62 | 7.09 | - |
| 2019 | -0.3 | 0.00 | 0.47 | 2.50 | - |
| 2020 | -3.3 | 0.04 | 13.25 | 354.10 | - |
| 2021 | -2.7 | 0.05 | 0.93 | 189.92 | - |
| 2022 | -0.7 | 0.13 | 0.48 | 60.13 | - |
| 2023 | -0.8 | 1.77 | 1.48 | 69.65 | - |
| 2024 | -0.3 | 0.00 | -0.44 | 61.01 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2015 | $-53,050.90 | $11.46M | $-23.98M | -209.3% |
| 2016 | $-999.70 | $5.55M | $-19.67M | -354.6% |
| 2017 | $-602.28 | $787K | $-24.09M | -3061.2% |
| 2018 | $-74.83 | $1.23M | $-20.57M | -1675.3% |
| 2019 | $-22.42 | $2.18M | $-21.5M | -985% |
| 2020 | $-2.17 | $231K | $-25.16M | -10890.5% |
| 2021 | $-0.96 | $226K | $-16.16M | -7151.8% |
| 2022 | $-0.91 | $226K | $-18.96M | -8391.2% |
| 2023 | $-0.90 | $226K | $-18.95M | -8384.1% |
| 2024 | $-6.58 | $226K | $-166.52M | -73682.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.31 | $-4.32 – $-2.30 | $300K | $300K – $300K | 1 |
| 2027 | $-3.00 | $-4.71 – $-1.29 | $13.1M | $13.1M – $13.1M | 2 |
| 2028 | $-0.69 | $-0.69 – $-0.69 | $57.1M | $57.1M – $57.1M | 1 |
| 2029 | $0.49 | $0.49 – $0.49 | $153.7M | $153.7M – $153.7M | 1 |
